Managerial Accounting Company Reviews and Performance Measures
Verified
Added on 2023/06/06
|10
|939
|288
AI Summary
This presentation provides an analysis of the remuneration committee and its membership, allocation of executive remuneration, mix of performance measures used, company performance versus executive pay, summary of findings, and conclusion of Mayne Pharma and CSL Limited.
Contribute Materials
Your contribution can guide someone’s learning journey. Share your
documents today.
MANAGERIAL ACCOUNTING Name of the Student: Name of the University: Author’s Note: Course ID:
Secure Best Marks with AI Grader
Need help grading? Try our AI Grader for instant feedback on your assignments.
Company reviews: Details of remuneration committee and its membership: •No evidences could be found about the members of the remuneration committee, while CSL Limited has three independent non-executive directors in its remuneration committee. •Timely meetings in a particular accounting year by taking into consideration external and internal conditions.
Company reviews (Continued): Allocation of executive remuneration: •In case of Mayne Pharma, fixed remuneration relies on the scope of executive role and their individual knowledge, skill and experience. In case of CSL, fixed remuneration includes base pay and superannuation reviewed annually and benchmark is set against comparable peer entities. •STIs rely on the results of the yearly corporate scorecard and individual performance in opposition to knowledge performance indicators. •LTIs are developed for aligning the executive as well as employee performance with the shareholders’ interest.
3. Company reviews (Continued): 3.3 Mix of performance measures used: •In case of Mayne Pharma, the earnings per share of the organisation have increased from 4.77 cents in 2016 to 6.18 cents in 2017, while the same has been $2.689 in 2016 compared to $2.937 in 2017. •However, for CSL Limited, the return on investment has fallen from 26.8% in 2016 to 24.5% in 2017. On the other hand, for Mayne Pharma, the return on capital invested has increased from 30% in 2016 to 32.60% in 2017.
Paraphrase This Document
Need a fresh take? Get an instant paraphrase of this document with our AI Paraphraser
3. Company reviews (Continued): 3.3 Mix of performance measures used (Continued): •Non-financial measure (Balanced scorecard): Financial perspective: •Mayne Pharma has the goal of minimising its business expenditures. This is accomplished by enhancing productivity along with optimising business processes. Customer perspective: •Mayne Pharma has developed a long-term plan for ensuring that adequate customers are generated to arrive at positive financial performance. Internal processes perspective: •After the customer requirements are identified, Mayne Pharma is engaged in cross-selling products due to the presence of proactive staffs. Learningand growth perspective: •Balanced scorecard is utilised for providing excess motivation to the staffs so that positive work outcomes could be assured.
3. Company reviews (Continued): 3.4 Company performance versus executive pay: •The share price of the organisation has been on the increasing scale and the current share price stands at $1.22. •After analysing the staff performance, Mayne Pharma has provided certain benefits in the form of short-term incentives and long-term incentives to its executive and non-executive members.
4. SUMMARY OF FINDINGS: •Mayne Pharma and CSL Limited conduct timely meetings in a particular accounting year by taking into consideration external and internal conditions. •Mayne Pharma has the goal of minimising its business expenditures. This is accomplished by enhancing productivity along with optimising business processes. For accomplishing the same, the organisation has formulated a five-year plan and the implementation process is carried out in distinct steps.
Secure Best Marks with AI Grader
Need help grading? Try our AI Grader for instant feedback on your assignments.
5. CONCLUSION: •Mayne Pharma and ASL Limited have developed remuneration committees for reviewing and recommending the executive compensation of the board committees. •However, in terms of financial performance in share market, Mayne Pharma is enjoying competitive advantage over CSL Limited and thus, it has increased its executive remuneration accordingly.
BIBLIOGRAPHIES: Annualreports.com., 2018. [online] Available at: http://www.annualreports.com/HostedData/AnnualReports/PDF/ASX_CSL_2017.pdf [Accessed 10 Sep. 2018]. Chen, L.H., Chung, H.H., Peters, G.F. and Wynn, J.P., 2016. Does Incentive-Based Compensation for Chief Internal Auditors Impact Objectivity? An External Audit Risk Perspective.Auditing: A Journal of Practice & Theory,36(2), pp.21-43. Fu, Y., Carson, E. and Simnett, R., 2015. Transparency report disclosure by Australian audit firms and opportunities for research.Managerial Auditing Journal,30(8/9), pp.870-910. Haque, F., 2017. The effects of board characteristics and sustainable compensation policy on carbon performance of UK firms.The British Accounting Review,49(3), pp.347-364. Ireland, I.N., 2016.Annual Report and Accounts for the Year Ended 31 March 2016. Invest NI. Kent, P., Kercher, K. and Routledge, J., 2018. Remuneration committees, shareholder dissent on CEO pay and the CEO pay–performance link.Accounting & Finance,58(2), pp.445-475. Maynepharma.com., 2018. [online] Available at: https://www.maynepharma.com/media/1964/2017-annual-report.pdf [Accessed 10 Sep. 2018]. Safari, M., Cooper, B.J. and Dellaportas, S., 2016. The influence of remuneration structures on financial reporting quality: evidence from Australia.Australian Accounting Review,26(1), pp.66-75. Skovoroda, R. and Bruce, A., 2017. Shifting the goalposts? Analysing changes to performance peer groups used to determine the remuneration of FTSE 100 CEOs.British Journal of Management,28(2), pp.265-279. Wagenhofer, A., 2016. Exploiting regulatory changes for research in management accounting.Management Accounting Research,31, pp.112-117.